Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
52-week range
$61.11 – $78.20
100% from low
Exchange
ARCX
ETF
Borrow rate
0.66%
Easy to borrow
No company description on file.
No one on the platform currently holds FHLC.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 3,597 | $267.2K |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-18 | $0.2630 | 2026-06-23 |
| 2026-03-20 | $0.2290 | 2026-03-24 |
| 2025-12-19 | $0.2720 | 2025-12-23 |
| 2025-09-19 | $0.2560 | 2025-09-23 |
| 2025-06-20 | $0.2570 | 2025-06-24 |
| 2025-03-21 | $0.2520 | 2025-03-25 |
| 2024-12-20 | $0.2580 | 2024-12-24 |
| 2024-09-20 | $0.2500 | 2024-09-24 |
| 2024-06-21 | $0.2420 | 2024-06-25 |
| 2024-03-15 | $0.2380 | 2024-03-20 |
No one on the platform has traded FHLC yet.
| +0.22% |
| $2.2B |
| — |
| FUTYFidelity MSCI Utilities Index ETF | $59.27 | -0.40% | $2.3B | — |
| MDYGState Street SPDR S&P 400 Mid Cap Growth ETF | $110.66 | +0.59% | $2.9B | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2023-12-15 |
| $0.2240 |
| 2023-12-20 |
| 2023-09-15 | $0.2190 | 2023-09-20 |
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$FHLC Current Stock Price: $74.45 Contracts to trade: $74.0 FHLC Feb 20 2026 Call Entry: $0.80 Exit: $1.57 ROI: 96% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗FDA To Ease Review Process For Life-Saving Gene-Editing Therapies: Report $ $IYH $FHLC https://stocktwits.com/news/equity/markets/fda-to-ease-review-process-for-life-saving-gene-editing-therapies-report/cLGq2wjR3UC
View on StockTwits ↗BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study $BTAI $FHLC $VXF https://stocktwits.com/news/equity/markets/bioxcel-stock-rises-pre-market-after-company-announces-positive-efficacy-data-for-agitation-drug-in-study/chwk7aERdub
View on StockTwits ↗Five Best Health Sector ETFs to Own Long-Term 1. $IHI - iShares U.S. Medical Devices ETF 2. $BBH - Virtus LifeSci Biotech Products ETF 3. $VHT - Vanguard Health Care ETF 4. $XLV - The Health Care Select Sector SPDR® Fund 5. $FHLC - Fidelity MSCI Health Care Index ETF
View on StockTwits ↗5 Best Health Sector ETFs to Own Long Term 1. $IHI - iShares U.S. Medical Devices ETF 2. $BBH - Virtus LifeSci Biotech Products ETF 3. $VHT - Vanguard Health Care ETF 4. $XLV - The Health Care Select Sector SPDR® Fund 5. $FHLC - Fidelity MSCI Health Care Index ETF
View on StockTwits ↗BioXcel’s Sublingual Film Well-Tolerated In Bipolar, Schizophrenia Trial In At-Home Settings, Retail Says Buy Now Or Regret Later $BTAI $FHLC $VXF https://stocktwits.com/news/equity/markets/bioxcel-sublingual-film-well-tolerated-in-bipolar-schizophrenia-trial-in-at-home-settings/chsU5sURdl5
View on StockTwits ↗@CreamCramer looks like $XLV & $FHLC are tracking nearly the same index. both have 0.08% expense ratio. FHLC is "more diversified", but XLV slightly outperformed in FHLC's inception. just a matter of preference on this one, imo
View on StockTwits ↗@Spks healthcare is a tricky sector to trade and invest. you’re not the first or last to witness this. there are too many reasons to list. if you want to invest/hold, just look at $xlv or $fhlc instead of individual tickers.
View on StockTwits ↗$FHLC $BVS $BCRX $AVBP https://wallstreetwaves.com/peek-under-the-hood-fhlc-has-21-upside/
View on StockTwits ↗5 Best Health Sector ETFs to Own Long Term $IHI – iShares U.S. Medical Devices ETF $XLV – The Health Care Select Sector SPDR® Fund $BBP – Virtus LifeSci Biotech Products ETF $VHT – Vanguard Health Care Index Fund ETF Shares $FHLC – Fidelity MSCI Health Care Index ETF https://deepvalueetfaccumulator.com/5-best-health-sector-etfs-to-own-long-term-2-9/
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.